Odrel® (Clopidogrel) is an inhibitor of ADP-induced platelet aggregation acting by direct inhibition of adenosine diphosphate (ADP) binding to its receptor and of the subsequent ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. Each tablet contains Clopidogrel Bisulfate INN equivalent to 75 mg Clopidogrel. Odrel® (Clopidogrel) is indicated for the reduction of atherosclerotic events (myocardial infarction, stroke and vascular death) in patients with atherosclerosis documented by recent stroke, recent myocardial infarction or established peripheral arterial disease.
- Convenience of once daily dosing
- Provides additive benefit in combination with aspirin
- Exerts proven cardiovascular benefits in PCI, stroke, STEMI & ACS
- Significant risk reduction of CV morbidity & mortality